New web tool aims to help young cancer patients plan families
NCT ID NCT06199726
First seen Nov 15, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who received cancer care at Moffitt Cancer Center will use the tool and rate its ease of use, confidence, and clarity. The goal is to see if the tool is helpful and easy to use, not to measure medical outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REPRODUCTIVE BEHAVIOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REFLECT web-based tool
What this could lead to
If successful, this tool could help young cancer patients make informed decisions about family building and genetic risks.
What could go wrong
This is a very small, early-stage study (16 people) focused on usability, not health outcomes. The tool may not be widely adopted or effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.